Combination therapy for depression
AssigneeThe General Hospital Corporation
InventorMaurizio Fava
Life of this patent
Estimating the term…
Abstract
A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT1A partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising this combination are also provided herein.
Claims32
A method of treating a depressive disorder in an individual comprising
- administering to the individual an amount of (1) bupropion and/or a salt, solvate, metabolite or racemate thereof, and an amount of (2) at least one serotonin 5-HT1A partial agonist and/or a salt, solvate, metabolite or racemate thereof, wherein the combined amount of (1) and the amount of (2) is effective for treatment of the depressive disorder.
-6. (canceled)
(canceled)
-12. (canceled)
A pharmaceutical formulation comprising an amount of (1) bupropion and/or a salt, solvate, metabolite or racemate thereof, and an amount of (2) at least one serotonin 5-HT1A partial agonist and/or a salt, solvate, metabolite or racemate thereof, wherein the combined amount of (1) and (2) is effective for treatment of depressive disorder.
(canceled)
(canceled)
A pharmaceutical product comprising
- a first formulation or unit dosage form comprising an amount of (1) bupropion and/or a salt, solvate, metabolite or racemate thereof, and an amount of (2) at least one serotonin 5-HT1A partial agonist and/or a salt, solvate, metabolite or racemate thereof, and
- a second formulation or unit dosage form comprising an amount of (1) but not (2) or an amount of (2) but not (1),
- wherein the combination of the first formulation or unit dosage form and the second formulation or unit dosage form is effective for treatment of a depressive disorder.
A pharmaceutical product comprising
- a first formulation or unit dosage form comprising an amount of bupropion and/or a salt, solvate, metabolite or racemate thereof, and
- a second formulation or unit dosage form comprising an amount of at least one serotonin 5-HT1A partial agonist and/or a salt, solvate, metabolite or racemate thereof,
- wherein the combination of the first formulation or unit dosage form and the second formulation or unit dosage form is effective for treatment of a depressive disorder.
(canceled)
(canceled)
Dependencies are inferred from the claim text.